Annovis Bio CEO Change and Director Departure
Ticker: ANVS · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors
TL;DR
Annovis Bio CEO Dr. Maccecchini takes board seat, Dr. Roeder exits board.
AI Summary
Annovis Bio, Inc. announced on December 4, 2024, the appointment of Dr. Maria L. Maccecchini as Chief Executive Officer and a member of the Board of Directors. Concurrently, Dr. Maccecchini stepped down from her role as Chief Scientific Officer. The company also announced the departure of Dr. Alan S. Roeder from the Board of Directors.
Why It Matters
This filing indicates a significant leadership change at Annovis Bio, with the CEO now also holding a board seat, which could signal a new strategic direction or increased focus on operational execution.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, impacting investor confidence.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- Dr. Maria L. Maccecchini (person) — Appointed CEO and Board Member
- Dr. Alan S. Roeder (person) — Departed Board Member
- December 4, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new CEO of Annovis Bio, Inc.?
Dr. Maria L. Maccecchini has been appointed as the new Chief Executive Officer of Annovis Bio, Inc.
What other role has Dr. Maria L. Maccecchini taken on?
Dr. Maria L. Maccecchini has also been appointed as a member of the Board of Directors.
What was Dr. Maria L. Maccecchini's previous role?
Dr. Maria L. Maccecchini previously served as the Chief Scientific Officer.
Who has departed from the Board of Directors?
Dr. Alan S. Roeder has departed from the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 4, 2024.
Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-12-09 16:15:34
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2430528d1_8k.htm (8-K) — 26KB
- 0001104659-24-126761.txt ( ) — 197KB
- anvs-20241204.xsd (EX-101.SCH) — 3KB
- anvs-20241204_lab.xml (EX-101.LAB) — 33KB
- anvs-20241204_pre.xml (EX-101.PRE) — 22KB
- tm2430528d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 4, 2024, Annovis Bio, Inc. ("Annovis") appointed William Fricker, age 61, to serve as Chief Financial Officer on an interim basis. Mr. Fricker most recently served as Chief Financial Officer of NeuroTrauma Sciences from December 2023 to April 2024. Prior to NeuroTrauma Sciences, Mr. Fricker served as an independent contractor providing CFO services to biotech companies from September 2021 to November 2023. From November 2020 to August 2021, Mr. Fricker served as CFO for NRX Pharmaceuticals, taking the Company public in May of 2020. Mr. Fricker served as Chief Accounting Officer for Immunomedics from February 2018 to the sale of the Company to Gilead in October 2020. Mr. Fricker started his career at PriceWaterhouseCoopers and has held management positions as Bristol Myers Squibb, Johnson & Johnson and Tyco. Mr. Fricker graduated from Penn State University with a B.S. in Accounting and is a CPA (Inactive). There are no transactions between Mr. Fricker and Annovis of the type required to be disclosed by Item 404(a) of Regulation S-K. Mr. Fricker is serving on a contract basis and is not a party to any employment agreement or similar arrangement with Annovis.
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: December 9, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer